Evaluation of the Effect of a Food Supplement Based on Hydrolyzed Collagen on Joint Function.
Unknown statusNot applicableNCT05917925
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This clinical study evaluates the effect of taking a hydrolyzed collagen-based supplement on pain, function and quality of life in a moderately physically active population. Non-pathological knee pain is a common occurrence in many healthy people and can limit the quality of life. Therefore, the resolution of this problem can bring many benefits in terms of quality of life.
Study details
- Official title
- Randomized, Double-blind Clinical Study to Evaluate the Effect of a Food Supplement Based on Hydrolyzed Collagen on Joint Function in a Moderately Active Population.
- Conditions
- Pain, Acute
- Pain, Chronic
- Knee Osteoarthritis
- Knee Injuries
- Interventions
- Dietary supplement: COLLAGEN (COL)
- Dietary supplement: PLACEBO (PLA)
- Sponsor
- Francisco Javier Martínez Noguera
- Collaborators
- San Antonio Technologies - San Antonio Catholic University of Murcia
- Organization
- Universidad Católica San Antonio de Murcia
- Start date
- 2023-04-01
- Primary completion
- 2024-02
- Sex
- All
- Age range
- from 18 Years to 60 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- Spain
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Individuals who exercise regularly and meet the WHO definition of being moderately active. * Persistent exercise-associated knee pain lasting at least 2 months prior to study inclusion. * Knee pain score on the visual analogue pain scale of at least 30 mm, taking into account that the scale has a maximum range of 100 mm. Exclusion Criteria: * Individuals with severe illness. * Subjects who are taking or have been treated within the last 7 days with glucosamine, chondroitin sulphate, collagen or hyaluronic acid injections or any dietary supplement indicated for joint health. * Subjects with chronic inflammatory diseases affecting the musculoskeletal apparatus. * Subjects with obesity (BMI ≥ 30 Kg/m2). * Allergy or known hypersensitivity to any of the ingredients in the investigational product. * Phenylketonuria. * Treatment with narcotics, steroidal anti-inflammatory drugs or immunosuppressants. - Symptoms of extreme pain requiring high doses of analgesic therapy for a period of time longer than 2 weeks or intra-articular injection treatment. * Individuals with diabetes. * Pregnant women. * Lactating women. * Subjects who are participating in a clinical trial. * Subjects who have participated in a clinical trial for pain in the last month.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05917925